This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Breslow, N. E. Articles by Green, D. M. Search for Related Content PubMed PubMed Citation Articles by Breslow, N. E. Articles by Green, D. M.

Renal Failure in the Denys-Drash and Wilms’ Tumor-Aniridia Syndromes¹

Department of Biostatistics, University of Washington, Seattle Washington 98195-7232 [N. E. B.]; Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 [J. R. T.]; Department of Surgery, University of Texas [M. L. R.] and Department of Experimental Pediatrics/Genetics, M. D. Anderson Cancer Center [L. C. S.], Houston, Texas 77030; and Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, New York 14203 [D. M. G.]

Nearly 6000 patients enrolled in four clinical trials of the National Wilms’ Tumor Study Group during 1969–1995 were followed until death or for a median of 11.0 years of survival for the onset of renal failure (RF). Thirteen of 22 patients with Denys-Drash syndrome and 10 of 46 patients with the Wilms’ tumor aniridia syndrome developed RF. The cumulative risks of RF at 20 years from Wilms’ tumor diagnosis were 62% and 38%, respectively. Only 21 cases of RF were observed among 5358 patients with unilateral disease who did not have characteristic congenital genitourinary anomalies, and their risk was <1%. Although other explanations cannot be completely excluded, the high rate of RF in patients with the aniridia syndrome challenges the view that nephropathy is associated uniquely with missense mutations in the WT1 gene. It suggests the possibility of a further gradation in the spectrum of phenotypes associated with different WT1 mutations. Patients with Wilms’ tumor and aniridia or genitourinary abnormalities should be followed closely throughout life for signs of nephropathy or RF.

This article has been cited by other articles:

				R H Scott, C A Stiller, L Walker, and N Rahman Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour J. Med. Genet., September 1, 2006; 43(9): 705 - 715. [Abstract] [Full Text] [PDF]

				B. V. Fischbach, K. L. Trout, J. Lewis, C. A. Luis, and M. Sika WAGR Syndrome: A Clinical Review of 54 Cases Pediatrics, October 1, 2005; 116(4): 984 - 988. [Abstract] [Full Text] [PDF]

				N. E. Breslow, R. Norris, P. A. Norkool, T. Kang, J. B. Beckwith, E. J. Perlman, M. L. Ritchey, D. M. Green, and K. E. Nichols Characteristics and Outcomes of Children With the Wilms Tumor-Aniridia Syndrome: A Report From the National Wilms Tumor Study Group J. Clin. Oncol., December 15, 2003; 21(24): 4579 - 4585. [Abstract] [Full Text] [PDF]

				C. E. Patek, S. Fleming, C. G. Miles, C. O. Bellamy, M. Ladomery, L. Spraggon, J. Mullins, N. D. Hastie, and M. L. Hooper Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis Hum. Mol. Genet., September 15, 2003; 12(18): 2379 - 2394. [Abstract] [Full Text] [PDF]

				K.-D. Wagner, N. Wagner, and A. Schedl The complex life of WT1 J. Cell Sci., May 1, 2003; 116(9): 1653 - 1658. [Abstract] [Full Text] [PDF]

				C. Loirat, J. L. Andre, J. Champigneulle, C. Acquaviva, D. Chantereau, R. Bourquard, J. Elion, and E. Denamur WT1 splice site mutation in a 46,XX female with minimal-change nephrotic syndrome and Wilms' tumour Nephrol. Dial. Transplant., April 1, 2003; 18(4): 823 - 825. [Full Text] [PDF]

				K Pritchard-Jones Controversies and advances in the management of Wilms' tumour Arch. Dis. Child., September 1, 2002; 87(3): 241 - 244. [Abstract] [Full Text] [PDF]